Non-peptide

SLU-PP-915

Also known as

SLU PP 915 · SLUPP915 · 915 · SLU-PP 915 · SLU-PP915 · oral ERR pan-agonist (915) · compound 10s (boronic acid pan-ERR) · 915 ERR agonist

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Experimental oral ERR compound	SLU-PP-915, or compound 10s, is a small molecule activating estrogen-related receptors involved in cellular energy-use genes. These are not classic estrogen receptors; it is not a peptide or SARM.
Different from 332	Oral capsules, tablets and powder attract interest as an alternative to SLU-PP-332. Equal labeled milligrams do not make the two molecules interchangeable.

Notes

A different molecule from SLU-PP-332. It activates estrogen-related receptors (ERRs), which help regulate cellular energy-use genes. Despite the name, these are not the classic estrogen receptors. Compound 10s is a synthetic small molecule, not a peptide or SARM. Hampton et al.: identification of SLU-PP-915 (10s), 2023 (Animal context · Accessed 2026-09-30)

Why oral use attracts attention. Community shorthand calls it the oral alternative to 332; capsules, tablets and bulk powder appear. Equal labeled milligrams are not interchangeable between these molecules.

Source context — Hampton et al.: identification of SLU-PP-915 (10s), 2023: Mouse/cell and liver-microsome experiments. Human liver microsomes are not living-human pharmacokinetics; no clinical safety or equivalence established.

What people notice

Easier cardio or nothing	Reports seek more sustainable cardio, less fade and training energy; some notice nothing. Energy sensations and wearable changes are not measured endurance or proven fat loss.
Positive stories need identity context	One apparent capsule success later involved possible mislabeling. Older 20 mg and 30 mg SLU reports may concern 332, so their endurance claims are not confirmed 915 outcomes.

Notes

More sustainable cardio and training. Discussion centers on endurance, less fade and zone-2 work. Reports range from easier sessions to nothing noticeable; energy sensations are not endurance measurements.

Cardio signals and null reports coexist. Existing logs find strength-only days flat, while others describe easier stamina or difficulty reaching zone 2. Lower resting heart rate/blood pressure claims are wearable talk, not cardiac clearance. Feeling nothing is not automatically a bad dose or fake product.

Fat loss remains hard to isolate. A September Eroids cutting thread seeks 915's energy appeal, but its OP had not tried it; a favorable reply concerned the original SLU. Several drugs and a calorie deficit complicate attribution. Considering an addition to the cut cycle: Mirabegron vs SLU-PP-915 (Community discussion · Accessed 2026-09-30)

Possible mislabeling leaves the cause of reported energy unresolved. A Peptide Critic author reports energy and late-cut changes on labeled 10 mg capsules, then reproduces seller messages suggesting a possible mislabeled blend. Similar energy with replacement leaves attribution unresolved; color cannot identify contents. Slu-pp-915 capsule powder color and replacement follow-up (Personal report · Accessed 2026-09-30)

The 20 mg and 30 mg reports need an identity caveat. In the older Reddit thread, one author reports a 20 mg daily tablet with BAM15, a planned 30-day cycle and day-20 endurance/focus improvements alongside slower recovery, lunchtime nodding and tendon/shoulder complaints. Another reports 30 mg on waking and at noon, easier cardio and evening exhaustion. The first later names 332; the OP corrects them. These are preserved ambiguous SLU accounts, not confirmed 915 outcomes. Slu-pp-915: thread with 332/915 identity confusion (Community discussion · Accessed 2026-09-30)

Source context — Considering an addition to the cut cycle: Mirabegron vs SLU-PP-915: Plans and beliefs do not establish outcomes or low cardiac risk. Multiple drugs and promotion badges; dose/benefit replies often concern 332 or mirabegron.

Source context — Slu-pp-915 capsule powder color and replacement follow-up: Page displays deleted-topic notice but actual body was returned and inspected. Coded research-animal/guinea-pig language is not a documented animal study or verified human identity. Seller messages are user-reproduced; contents never assayed here. Color cannot identify a chemical.

Source context — Slu-pp-915: thread with 332/915 identity confusion: Anonymous unverified tablets. The 20 mg reporter later explicitly names 332; OP corrects the identity. The 30 mg report says only Slu. Neither is confidently a 915 experience. Relative timestamps not converted.

Doses people talk about

Oral microdose reports	250–500 mcg per administration, about 20 minutes before training, appears with inconsistent frequency. This equals 0.25–0.5 mg, separate from higher capsule claims.
Oral training-day split	One account describes 2 mg before fasted cardio plus 2 mg before lifting: 4 mg that day, not an established daily total for others.
Capsule log without outcomes	A published log records 10, then 20, then 30 mg/day orally after waking. Outcomes remain unreported; it is not evidence of success or nonresponse.
Disputed or scaled amounts	The 2-versus-20 mg argument has no resolved effective dose. Proposed 100 mg tablets and 100–200 mg scaling claims are guesses from animal work, not observed effective human exposure.

Notes

Oral microdose reports: 250–500 mcg per administration. Existing notes place these roughly 20 minutes before training, with warmth, crash or reflux in one account. Frequency is inconsistently recorded. They equal 0.25–0.5 mg, separate from capsule-dose claims.

A separate split report: 2 mg plus 2 mg. One account described oral use before fasted cardio and again before lifting: 4 mg total that day, not a daily standard.

A fresh log: 10, then 20, then 30 mg/day orally. N=1 After 40 records capsules after waking, starting August 20, 2026 and reaching 30 mg/day by September 22. Outcomes remain unreported. SLU-PP-915 personal experiment, September 2026 (Personal report · Accessed 2026-09-30)

20 mg versus 2 mg is an unresolved argument. Surviving Reddit comments call 2 mg already high; the deleted author calls 20 mg low and proposes 100 mg tablets from guessed animal comparisons. Proposed use is not an observed effective dose. 20MG SLU-PP-915 Experiment: surviving comments (Community discussion · Accessed 2026-09-30)

Higher scaling claims are a different category. A Rapamycin forum post speculates about 40 mg initially and 100–200 mg at 64 kg: mouse-to-human extrapolation, not observed exposure. SLU-PP discussion: oral-915 scaling speculation (Community opinion · Accessed 2026-09-30)

Source context — SLU-PP-915 personal experiment, September 2026: Personal published log; three early administrations mentioned but ledger not independently inspected. Ongoing experiment is not nonresponse or success. Unverified capsules and co-use.

Source context — 20MG SLU-PP-915 Experiment: surviving comments: OP deleted and locked; comments inspected, not original outcome report. Proposed 100 mg is an intention, not observed use; dosing guessed and identity disputed.

Source context — SLU-PP discussion: oral-915 scaling speculation: 40 mg and 100–200 mg at 64 kg are speculative mouse-derived estimates, not reported human efficacy doses. Thread includes AI-produced summaries and vendor-related discussion; neither adopted as formal evidence.

Half-life, onset & duration

Felt onset	No established onset. Twenty minutes before training is a habit in microdose logs; same-day warmth or energy and first-week experiences do not measure absorption or endurance onset.
Felt duration	No reliable one-dose benefit window. Session effects, later exhaustion and stronger or longer caffeine sensations cannot establish coverage or a repeat interval.
Half-life	Human oral half-life is unknown here. The measured 18–28 minutes was mouse plasma; greater than 60 minutes in liver preparations is not clearance in a living human.

Notes

A pre-training habit is not a proven onset. The 20-minute timing comes from oral microdose logs. Same-day warmth/energy and first-week experiences are mixed; these accounts do not measure absorption or endurance onset.

No reliable single-dose benefit window. Accounts describe sessions, later couch crash or repeated-use changes. Stronger or longer caffeine sensations also appear; none establishes a redosing interval or lasting adaptation.

No established human oral half-life in these accounts. Community notes acknowledge missing human pharmacokinetic data. Twice-daily habits cannot measure clearance. Mouse plasma and liver-microsome numbers appear separately below.

Mouse plasma: 18–28 minutes. Billon measured this after oral gavage at 2, 8 and 32 mg/kg. The study used 0.2–32 mg/kg oral/IP experiments and seven-day regimens. Its one-hour acute/repeated plasma comparison found no accumulation. These are mouse measurements, not human timing or cycles; some treadmill comparisons improved about 50%. Billon et al.: orally active SLU-PP-915, 2026 (Animal context · Accessed 2026-09-30)

Liver microsomes: greater than 60 minutes. Hampton found this for 10s in mouse and human liver preparations, and studied 20 mg/kg intraperitoneally in mice with one-hour gene/performance readouts. A liver preparation is not a person; this value cannot replace human plasma half-life. Hampton et al.: identification of SLU-PP-915 (10s), 2023 (Animal context · Accessed 2026-09-30)

Source context — Billon et al.: orally active SLU-PP-915, 2026: Primary paper in community-hosted mirror; male mice, experimental oral suspension/IP routes. No human dose, clearance, benefit duration or long-term safety. Publisher direct routes failed.

Cycles people discuss

Informal blocks	2–4-week checks and 4–8-week extended experiments appear. A deleted author described a four-week capsule experiment, but the original outcomes were inaccessible.
No settled break	Daily, pulsed and differing off-period habits coexist. Switching after disappointing oral 332 is a sequence, not evidence for combining the two or a validated cycle.

Notes

Two-to-four-week checks; four-to-eight-week extended experiments. These are patterns in the community record. The deleted Reddit author describes a four-week capsule experiment, without accessible original outcomes. They are informal blocks, not an optimal or safe cycle. 20MG SLU-PP-915 Experiment: surviving comments (Community discussion · Accessed 2026-09-30)

Daily, pulsed and off-period habits differ. No shared break length is established. Switching after disappointing oral 332 also appears, alongside people waiting for better feedback; that selection can favor enthusiastic switch stories.

Failed oral 332 → 915 switch: Common narrative stack path (sequential, not simultaneous). [anecdote]

Stacks

Multi-compound energy stacks	Preserved lists include MOTS-c, NAD+, methylene blue and 915 together, plus 5-Amino-1MQ/SS-31 cutting stacks. Their reports do not isolate 915; other discussions also name GLP-1 drugs and ATX-304.
BAM15 and 332 confusion	A 20 mg tablet account involved BAM15, but the author later named 332. It remains an ambiguous SLU combination, not confirmed 915 co-use; comparing or switching from 332 is a different claim.

Notes

Multiple-compound list (2026 X): MOTS-c + NAD+ + methylene blue + 915 appears in a screenshot promising a noticeable effect. The list cannot establish use, benefit or which ingredient caused a change. [community]

5-Amino-1MQ / SS-31 cut stacks: Named next to 915 in the same metabolic-chem month; contest-prep logs still credit deficit and cardio first. [community]

Stacks and meal habits complicate attribution. BAM15, MOTS-c, 5-Amino-1MQ, GLP-1 drugs, NAD+, methylene blue, SS-31 and ATX-304 appear alongside 915. Fasted-cardio use and food for reflux both occur. More compounds or stronger caffeine feelings obscure which substance caused benefit or trouble.

Watch for

Heat, reflux and wired-then-flat feelings	915-labeled notes include warmth, bad taste, tingling, reflux and later exhaustion, with caffeine in one account. Broader 332 complaints cannot supply a 915 side-effect rate.
Identity and unknown combinations	Possible mislabeled blends and 332 confusion limit interpretation. Long-term human effects and interactions remain unknown; an assay or research-use label does not establish safety or sports clearance.

Notes

Heat, reflux and feeling wired then flat. Existing 915-labeled notes include bad taste, arm tingling, later exhaustion and stimulant-like feelings even at 500 mcg. Caffeine confounds that account. Broader ERR-class heat and sleep complaints often concern 332 and are not measured 915 side-effect rates.

Unknown interactions and long-term effects. Community concern includes mixing pan-ERR compounds, medications and other metabolic agents. A research-use label or capsule assay cannot establish human safety. Sports-testing interest also makes assumed clearance windows unreliable.

Full notes

SLU-PP-915 is an experimental small molecule discussed as an oral endurance and cutting compound. People seek easier cardio or more training energy, but the reports disagree sharply about amounts and effects. Confusion with SLU-PP-332 and uncertain capsule contents make confident conclusions difficult.

What SLU-PP-915 actually is

A different molecule from SLU-PP-332. It activates estrogen-related receptors (ERRs), which help regulate cellular energy-use genes. Despite the name, these are not the classic estrogen receptors. Compound 10s is a synthetic small molecule, not a peptide or SARM. Animal context
Why oral use attracts attention. Community shorthand calls it the oral alternative to 332; capsules, tablets and bulk powder appear. Equal labeled milligrams are not interchangeable between these molecules. Community Community

What people hope to get

More sustainable cardio and training. Discussion centers on endurance, less fade and zone-2 work. Reports range from easier sessions to nothing noticeable; energy sensations are not endurance measurements. Community Community
Fat loss remains hard to isolate. A September Eroids cutting thread seeks 915's energy appeal, but its OP had not tried it; a favorable reply concerned the original SLU. Several drugs and a calorie deficit complicate attribution. Eroids

Doses people discuss

Reported amounts, not instructions. mcg means micrograms; 1,000 mcg equals 1 mg. Labeled contents and absorbed amounts are different questions.

Oral microdose reports: 250–500 mcg per administration. Existing notes place these roughly 20 minutes before training, with warmth, crash or reflux in one account. Frequency is inconsistently recorded. They equal 0.25–0.5 mg, separate from capsule-dose claims. Community Community
A separate split report: 2 mg plus 2 mg. One account described oral use before fasted cardio and again before lifting: 4 mg total that day, not a daily standard. Community
A fresh log: 10, then 20, then 30 mg/day orally. N=1 After 40 records capsules after waking, starting August 20, 2026 and reaching 30 mg/day by September 22. Outcomes remain unreported. Personal report
20 mg versus 2 mg is an unresolved argument. Surviving Reddit comments call 2 mg already high; the deleted author calls 20 mg low and proposes 100 mg tablets from guessed animal comparisons. Proposed use is not an observed effective dose. Reddit
Higher scaling claims are a different category. A Rapamycin forum post speculates about 40 mg initially and 100–200 mg at 64 kg: mouse-to-human extrapolation, not observed exposure. Rapamycin Longevity News

Half-life

No established human oral half-life in these accounts. Community notes acknowledge missing human pharmacokinetic data. Twice-daily habits cannot measure clearance. Mouse plasma and liver-microsome numbers appear separately below. Community

Onset: when people notice something

A pre-training habit is not a proven onset. The 20-minute timing comes from oral microdose logs. Same-day warmth/energy and first-week experiences are mixed; these accounts do not measure absorption or endurance onset. Community

Duration: how long effects last

No reliable single-dose benefit window. Accounts describe sessions, later couch crash or repeated-use changes. Stronger or longer caffeine sensations also appear; none establishes a redosing interval or lasting adaptation. Community

Cycles and time off

Two-to-four-week checks; four-to-eight-week extended experiments. These are patterns in the community record. The deleted Reddit author describes a four-week capsule experiment, without accessible original outcomes. They are informal blocks, not an optimal or safe cycle. Community Reddit
Daily, pulsed and off-period habits differ. No shared break length is established. Switching after disappointing oral 332 also appears, alongside people waiting for better feedback; that selection can favor enthusiastic switch stories. Community

Unwanted effects and uncertainties

Heat, reflux and feeling wired then flat. Existing 915-labeled notes include bad taste, arm tingling, later exhaustion and stimulant-like feelings even at 500 mcg. Caffeine confounds that account. Broader ERR-class heat and sleep complaints often concern 332 and are not measured 915 side-effect rates. Community Community
Unknown interactions and long-term effects. Community concern includes mixing pan-ERR compounds, medications and other metabolic agents. A research-use label or capsule assay cannot establish human safety. Sports-testing interest also makes assumed clearance windows unreliable. Community Community

From community discussion

Possible mislabeling leaves the cause of reported energy unresolved. A Peptide Critic author reports energy and late-cut changes on labeled 10 mg capsules, then reproduces seller messages suggesting a possible mislabeled blend. Similar energy with replacement leaves attribution unresolved; color cannot identify contents. Personal report
The 20 mg and 30 mg reports need an identity caveat. In the older Reddit thread, one author reports a 20 mg daily tablet with BAM15, a planned 30-day cycle and day-20 endurance/focus improvements alongside slower recovery, lunchtime nodding and tendon/shoulder complaints. Another reports 30 mg on waking and at noon, easier cardio and evening exhaustion. The first later names 332; the OP corrects them. These are preserved ambiguous SLU accounts, not confirmed 915 outcomes. Reddit
Polls describe disagreement, not successful doses. The frozen X summary records 116 votes: about 34% selected 1 mg, 24% 10 mg, 26% 20 mg and 16% other. A smaller poll spans 0–1, 2–10 and 11–20 mg. Neither verifies use, route or benefit. Community
Cardio signals and null reports coexist. Existing logs find strength-only days flat, while others describe easier stamina or difficulty reaching zone 2. Lower resting heart rate/blood pressure claims are wearable talk, not cardiac clearance. Feeling nothing is not automatically a bad dose or fake product. Community Community
Comparison claims conflict. A Rapamycin commenter relays a creator's fivefold-effectiveness claim; another says some experimenters preferred 332. Neither establishes a conversion ratio. Better oral design does not prove that every disappointing oral-332 report was placebo. Rapamycin Longevity News Community
Stacks and meal habits complicate attribution. BAM15, MOTS-c, 5-Amino-1MQ, GLP-1 drugs, NAD+, methylene blue, SS-31 and ATX-304 appear alongside 915. Fasted-cardio use and food for reflux both occur. More compounds or stronger caffeine feelings obscure which substance caused benefit or trouble. Community Community

What the laboratory numbers describe

Mouse plasma: 18–28 minutes. Billon measured this after oral gavage at 2, 8 and 32 mg/kg. The study used 0.2–32 mg/kg oral/IP experiments and seven-day regimens. Its one-hour acute/repeated plasma comparison found no accumulation. These are mouse measurements, not human timing or cycles; some treadmill comparisons improved about 50%. Animal context
Liver microsomes: greater than 60 minutes. Hampton found this for 10s in mouse and human liver preparations, and studied 20 mg/kg intraperitoneally in mice with one-hour gene/performance readouts. A liver preparation is not a person; this value cannot replace human plasma half-life. Animal context
Cardiac benefit belongs to a disease model. Xu reports better ejection fraction, less fibrosis and greater survival in pressure-overload mice, without changing hypertrophy. This supports research interest, not safety assurance for healthy people seeking performance. Animal context